Agencies agree to purchase investigational antiviral if authorized by FDA
The departments of Health and Human Services and Defense will purchase 1.7 million treatment courses of an investigational antiviral drug for $1.2 billion if the Food and Drug Administration approves or authorizes the therapy, the Biden administration announced today.
If authorized, the federal government will allocate the drug (molnupiravir) to states and territories. Health care providers would order the drug directly from the distributor within those allocations, HHS said.
Related News Articles
Chairperson's File
We’re at a watershed moment in health care, which gives us opportunities to strengthen how we serve patients and communities. Health care leaders must help…
Perspective
This week, more than 1,000 hospital and health system leaders came to Washington, D.C., united by a shared responsibility: to ensure every community has access…
Perspective
Two days from now, the AHA will welcome more than 1,000 health care leaders to our 2026 Annual Membership Meeting in Washington, D.C.This yearly gathering…
Headline
Secretary of Health and Human Services Robert F. Kennedy Jr. April 16 testified during two House hearings on the HHS fiscal year 2027 budget proposal, which…
Perspective
Just 23 days from now, more than 1,000 hospital and health system leaders from across the country will arrive in Washington, D.C., for the 2026 AHA Annual…
Headline
The White House today released its national policy framework on artificial intelligence. The framework includes several recommendations for Congress…